Biohaven Ltd logo

Biohaven Ltd

$ 13.75 -0.19 (-1.36%) 08:08 PM EST
At Loss
Market Cap:
$ 937.21M
Enterprise V:
$ 899.50M
Avg Vol (2M):
Market Cap $:
PE Ratio:
At Loss
Avg Vol (2M):
Enterprise Value $:
PB Ratio:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for BHVN ( Biohaven Ltd ) from 2022 to Mar 21 2023. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Biohaven stock (BHVN) PE ratio as of Mar 21 2023 is 0. More Details

Biohaven Ltd (BHVN) PE Ratio (TTM) Chart


Biohaven Ltd (BHVN) PE Ratio (TTM) Historical Data

Total 123
  • 1
  • 2
Biohaven PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2023-03-22 At Loss 2023-01-13 At Loss
2023-03-20 At Loss 2023-01-12 At Loss
2023-03-17 At Loss 2023-01-11 At Loss
2023-03-16 At Loss 2023-01-10 At Loss
2023-03-15 At Loss 2023-01-09 At Loss
2023-03-14 At Loss 2023-01-06 At Loss
2023-03-13 At Loss 2023-01-05 At Loss
2023-03-10 At Loss 2023-01-04 At Loss
2023-03-09 At Loss 2023-01-03 At Loss
2023-03-08 At Loss 2022-12-30 At Loss
2023-03-07 At Loss 2022-12-29 At Loss
2023-03-06 At Loss 2022-12-28 At Loss
2023-03-03 At Loss 2022-12-27 At Loss
2023-03-02 At Loss 2022-12-23 At Loss
2023-03-01 At Loss 2022-12-22 At Loss
2023-02-28 At Loss 2022-12-21 At Loss
2023-02-27 At Loss 2022-12-20 At Loss
2023-02-24 At Loss 2022-12-19 At Loss
2023-02-23 At Loss 2022-12-16 At Loss
2023-02-22 At Loss 2022-12-15 At Loss
2023-02-21 At Loss 2022-12-14 At Loss
2023-02-17 At Loss 2022-12-13 At Loss
2023-02-16 At Loss 2022-12-12 At Loss
2023-02-15 At Loss 2022-12-09 At Loss
2023-02-14 At Loss 2022-12-08 At Loss
2023-02-13 At Loss 2022-12-07 At Loss
2023-02-10 At Loss 2022-12-06 At Loss
2023-02-09 At Loss 2022-12-05 At Loss
2023-02-08 At Loss 2022-12-02 At Loss
2023-02-07 At Loss 2022-12-01 At Loss
2023-02-06 At Loss 2022-11-30 At Loss
2023-02-03 At Loss 2022-11-29 At Loss
2023-02-02 At Loss 2022-11-28 At Loss
2023-02-01 At Loss 2022-11-25 At Loss
2023-01-31 At Loss 2022-11-23 At Loss
2023-01-30 At Loss 2022-11-22 At Loss
2023-01-27 At Loss 2022-11-21 At Loss
2023-01-26 At Loss 2022-11-18 At Loss
2023-01-25 At Loss 2022-11-17 At Loss
2023-01-24 At Loss 2022-11-16 At Loss
2023-01-23 At Loss 2022-11-15 At Loss
2023-01-20 At Loss 2022-11-14 At Loss
2023-01-19 At Loss 2022-11-11 At Loss
2023-01-18 At Loss 2022-11-10 At Loss
2023-01-17 At Loss 2022-11-09 At Loss

Biohaven Ltd (BHVN) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Traded in other countries / regions
IPO Date
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on discovering and developing therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, immunology, and disease-related biology, including rare disorders. Its neuroscience portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7, glutamate receptors, myostatin, and TRP channels. Its products target diseases such as migraine, depression, bipolar, and schizophrenia.